Loading…
← CockpitCompetitor Analysis › 4553.T Towa Pharmaceutical Co., Ltd.Open in the cockpit ↗

Towa Pharmaceutical Co., Ltd.4553.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese manufacturer of generic (off-patent) pharmaceutical drugs sold to hospitals and pharmacies.

≈ Japan's Teva / ViatrisMomentum weak 30
Mkt cap
$1.03B
US dollars, full cap
Free float
47%
of shares outstanding
$/day
$3.51M
20-day average traded
Fwd P/E
7.7×
forward earnings
ROIC−WACC
-0.2 pp
WACC 5.0%
Hurdle
-12 pp
Req g minus delivered
Next earnings
89 days
15 Feb 2027
Close · JPY¥3,390
1D0.0%
1W-2.0%
1M-6.9%
3M-10.7%
6M-10.3%
YTD-6.9%
1Y+20.2%
ATR %3.4%
52w lowhigh24.5% off high

What Towa Pharmaceutical does

Japanese manufacturer of generic (off-patent) pharmaceutical drugs sold to hospitals and pharmacies.

Prices for its drugs are set on the government's reimbursement list and cut regularly, so it competes on volume gained when doctors and pharmacies switch patients to generics and on production cost, since the selling price is not negotiable. It also makes drugs on contract for other pharma companies.

In one line: Japan's Teva / Viatris.

Products and services

  • Generic prescription drugs
  • Contract manufacturing for other pharma

Customers

  • Hospitals
  • Pharmacies
  • Health insurers (via reimbursement)

Where it sits in the supply chain

  • Health care
  • Generic pharmaceuticals
  • Generic drug manufacturing and sales

What could go right

  • Government push for generic drug substitution

What could go wrong

  • Recurring government-mandated generic price cuts

Moat: none (scale, regulatory licence). Generic drug maker competing on cost and government-mandated price cuts, with little product differentiation.

Headquarters: Osaka, Japan · Founded: 1951 · Employees: 4,923

Named competitors

Towa Pharmaceutical at a glance

Size Towa Pharmaceutical (4553.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.03B, the 726th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,390 on 18 Nov 2026.

Performance Over six months the shares fell 10.3%, against -11.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 7.1% over the last twelve months (peer median +3.9%); the operating margin is 8.9% (peer median 7.4%).

Valuation It trades at 7.7× forward earnings against a peer median of 18.3× (3rd cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.2 points below its cost of capital (5.0% WACC).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 20264553.T 91Peer median 90
Six months, rebased to 100: Towa Pharmaceutical against the median of its 20 peers (local-currency closes).

Towa Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥285B¥274B¥260B¥228B¥209B
Revenue growth—+5%+14%+9%—
Gross profit¥103B¥99.1B¥94.7B¥81.4B¥72.7B
EBITDA¥47.7B¥45.9B¥43.3B¥35.5B¥24.9B
Net income¥3.90B¥5.25B¥19.0B¥16.2B¥2.20B
Free cash flow¥10.9B¥8.15B-¥5.33B-¥29.6B-¥26.2B
Capital expenditure¥17.7B¥24.1B¥31.2B¥39.3B¥30.5B
Total debt¥230B¥227B¥231B¥202B¥162B

Quarterly statements and history in the cockpit →

Towa Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%002737688513SVRA300497BSLN600789BLUEJET30070219520006504887688091605116688710600557OMER600812AARTIPHARM6883826001294553.T6-month return →1-month return →
Up and to the right = strong over both horizons. Towa Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×20×40×60×002737688513300497BSLNBLUEJET300702195200065048876051166887106001294553.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Towa Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%002737688513300497BSLNBLUEJET0006506051166887106008126883824553.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Towa Pharmaceutical is the large dot.

Towa Pharmaceutical competitors and peer comparison

Head to head with its named competitors (4553.T vs 4887.T vs VTRS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Towa Pharmaceutical 4553.T$1.03B-10%+7%9%7.7×-0.3%
SAWAI 4887.T$1.01B-18%+2%9%12.0×n/a
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%

How Towa Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Towa Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4553.TPeer medianRank in peer set
1-month return-6.9%-9.8%10th highest of 21
6-month return-10.3%-11.9%9th highest of 21
Distance from 52-week high-24.5%-32.4%6th highest of 21
Revenue growth (TTM)+7.1%+3.9%9th highest of 19
Operating margin8.9%7.4%9th highest of 20
Forward P/E7.7×18.3×3rd cheapest of 15
Growth the price implies (Req g, 7 yrs)-0.3%2.5%5th least demanding of 14
Growth delivered (Del g)+12.1%+3.5%5th highest of 14
Hurdle (Req g minus delivered)-12.4 pp+0.5 pp3rd least demanding of 14
ROIC minus cost of capital-0.2 pp+0.1 pp10th highest of 19
EV / EBITDA7.1×16.3×cheapest of 5
Net debt / EBITDA3.5×-1.3×most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a

Questions

Who are Towa Pharmaceutical's main competitors?
Named competitors: Sawai Group Holdings (4887.T), Nichi-Iko Pharmaceutical (private or unlisted), Viatris (VTRS). The cockpit's measured peer set (industry) also includes Sunflower Pharmaceutical (002737.SZ), Chengdu Easton Biopharmaceuticals (688513.SS), Savara (SVRA), Jiangxi Fushine Pharmaceutical (300497.SZ), Basilea Pharmaceutica (BSLN.SW), Shandong Lukang Pharmaceutical (600789.SS).
Is Towa Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 7.7× against a peer median of 18.3×, 3rd cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Towa Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -10.3% against -11.9% for the median peer; over one year +20.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.